Press Releases

Transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity into equity of the combined company Transaction expected to provide up to $113 million of cash

SAN FRANCISCO-Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointments of Andrew Armanino and Geoffrey Parker to its board of directors.

Justin Zamirowski to lead upcoming launches of Better Therapeutics’ maturing prescription digital therapeutics product portfolio with a near term focus on type 2 diabetes and associated comorbidities. We recently  announced  the appointment of Justin Zamirowski as Chief Commercial Officer.

Data from a clinical study of Better’s prescription digital therapeutic in patients with type 2 diabetes will be presented at the upcoming Endocrine 2020 Conference. The conference will take place on March 28-31, at San Francisco’s Moscone Center. Highlights of the study include: Mean reduction in

Today, we announced the publication of our  fifth peer-reviewed study  titled "Estimating the impact of novel digital therapeutics in type 2 diabetes and hypertension: Health economic analysis." Key findings were presented earlier this year at The International Society for Pharmacoeconomics and

Machine learning transformed data from using a digital therapeutic into digital biomarkers that predicted treatment response in individual participants. Today, we  announced  the  publication  of our latest study titled "Emergence of digital biomarkers to predict and modify treatment efficacy: a

With a highly regarded career designing products for startups, growth and enterprise companies, Kristin leads Better’s product design and branding functions as Head of Design. Kristin is a Silicon Valley native and a veteran of the tech industry since 1996.

Today, Better announced the publication of its latest peer-reviewed clinical study in hypertension, titled "Achieving Rapid Blood Pressure Control With a Digital Therapeutic: A Retrospective Cohort and Machine Learning Study." The study was  published  in JMIR Cardio.

Individuals with diabetes lowered A1c by an average of -.8%; further improvement was observed following the treatment period 91% of individuals with hypertension lowered blood pressure; systolic BP reduced by an average of -11.4 mmHg Today, at the annual meeting of the American College of Lifestyle

Results of our peer-reviewed clinical study published today in the  Journal of Medical Internet Research  demonstrate the potential for lifestyle therapy, delivered as a digital therapeutic, to become a widely-accessible and affordable solution for treating individuals with type II diabetes.